3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
8
Sarcoma
2
Genitourinary
2
Breast
2
Tumor-Agnostic
1
Thoracic
1
Plasma cell
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Conditions
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Interventions
Carboplatin
347
pembrolizumab
322
Pemetrexed
246
Cisplatin
218
Paclitaxel
147
Nivolumab
138
durvalumab
133
osimertinib
112
Docetaxel
111
atezolizumab
109
Specimen Handling
91
Radiotherapy
87
Drug Therapy
85
Magnetic Resonance Spectroscopy
77
Etoposide
76
Radiosurgery
72
Gemcitabine
71
Ipilimumab
55
130-nm albumin-bound paclitaxel
54
Bevacizumab
52
cemiplimab
47
tislelizumab
44
Blood Specimen Collection
40
Cetuximab
35
Taxes
34
Platinum
33
Injections
33
Biopsy
33
Standard of Care
31
Immunoglobulin G
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
futibatinib
×
Thoracic
×
1 year
×
Clear all
NCT05827614
2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1
Active not recruiting
85 enrolled